Akebia Therapeutics (AKBA) Financial Statements & Analysis

Akebia Therapeutics (AKBA) Income Statement

Akebia Therapeutics reported revenue of $236.20M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 47.5% from $160.18M a year earlier. Akebia Therapeutics posted a net loss of $5.34M, compared with a net loss of $69.41M a year earlier. Gross margin was 83.3% and operating margin 9.9%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $49.13M, down 21.4% from the same quarter a year earlier.

Akebia Therapeutics Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Akebia Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	236.20	160.18	194.62	292.48	211.65	294.64	335.00	207.74	177.98
Cost of Revenue	39.46	63.18	74.15	22.50	150.67	63.96	145.34	7.69	0.62
Gross Profit	196.73	97.00	120.47	206.92	60.98	230.68	189.67	200.06	177.37
Operating Expenses
Research & Development	62.36	37.65	63.08	129.99	147.85	218.49	322.97	291.07	230.89
Selling, General & Administrative	107.48	106.55	100.23	138.60	174.14	154.10	149.46	87.06	27.01
Operating Expenses	173.24	147.42	166.73	287.70	325.48	405.20	475.95	378.20	257.90
Operating Income	23.50	-50.41	-46.26	-80.78	-264.50	-174.52	-286.29	-178.14	-79.92
Other Income/Expense
Interest Income	0.00	0.00	0.00	0.00	0.07	0.00	2.19	6.15	2.80
Interest Expense	24.18	18.19	6.03	-15.69	19.94	-8.92	1.40	0.00	0.00
Other Income/Expense	-27.22	-0.81	-5.67	-13.45	2.41	1.86	0.00	6.24	3.00
Income
Income Before Tax	-3.72	-69.41	-51.93	-94.23	-282.02	-384.84	-286.29	-171.90	-76.91
Income Tax Expense	1.62	0.00	0.00	0.00	0.00	0.00	-6.63	-28.34	-2.80
Net Income	-5.35	-69.41	-51.93	-94.23	-282.02	-384.84	-279.66	-171.90	-76.91
Net Income - Continuous Operations	-5.35	-69.41	-51.93	-94.23	-282.02	-384.84	-279.66	-171.90	-76.91
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-
EBITDA	21.73	-13.72	-8.27	3.06	-226.53	-139.83	-249.87	-178.09	-76.06
EBIT	26.00	-51.23	-44.50	-34.64	-264.50	-174.52	-	-	-
Depreciation & Amortization	1.27	37.50	37.63	37.70	37.97	34.69	36.42	2.42	0.62
Earnings Per Share
Basic EPS	-	-	-	-1.00	-2.00	-3.00	-2.00	-1.00	-2.00
Diluted EPS	-	-	-	-1.00	-2.00	-3.00	-2.00	-1.00	-2.00
Basic Shares Outstanding	257.16	210.95	187.47	182.78	165.95	138.46	118.40	116.89	43.50
Diluted Shares Outstanding	257.16	210.95	187.47	182.78	165.95	138.46	118.40	116.89	43.50

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Akebia Therapeutics Financial Statements

What was Akebia Therapeutics's revenue in fiscal 2025?

Akebia Therapeutics reported revenue of $236.20M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 47.5% from $160.18M a year earlier.

Is Akebia Therapeutics profitable?

No. Akebia Therapeutics reported a net loss of $5.34M in fiscal 2025. In fiscal 2024 it lost $69.41M.

What is Akebia Therapeutics's operating margin?

Akebia Therapeutics's operating income was $23.50M on revenue of $236.20M in fiscal 2025, an operating margin of 9.9%, compared with -31.5% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition